The object of this study was to determine whether prostaglandin E., (PGE2) can prevent ovariectomyinduced cancellous bone loss. Thirty-five 3-month-old female Sprague-Dawley rats were divided into two groups. The rats in the first group were ovariectomized (OVX) while the others received sham operation (sham-OVX). The OVX group was further divided into three treatment groups. The daily doses for the three groups were 0, 1 and 6 mg PGE,/kg for 90 days. Bone histomorphometric analyses were performed on double-fluorescent-labeled undecalcified proximal tibial metaphysis (PTM). We confirmed that OVX induces massive cancellous bone loss (-80%) and a higher bone turnover (+ 143%). The new findings from the present study demonstrate that bone loss due to ovarian hormone deficiency can be prevented by a low-dose (1 mg) daily administration of PGE2. Furthermore, a higher-dose (6 mg) daily administration of PGE2 not only prevents bone loss but also adds extra bone to the proximal tibial metaphyses. PGE_, at the l-mg dose level significantly increased trabecular bone area, trabecular width, trabecular node density, density of node to node, ratio of node to free end, and thus significantly decreased trabecular separation from OVX controls. At this dose level, these same parameters did not differ significantly from sham-OVX controls. However, at the 6-mg dose level PGEz, there were significant increases in trabecular bone area, trabecular width, trabecular node density, density of node to node, and ratio of node to free end, while there was significant decrease in trabecular separation from both OVX and sham-operated controls. The changes in indices of trabecular bone microanatomical structure indicated that PGE2 prevented bone loss as well as the disconnection of existing trabeculae. In summary, PGE2 administration to OVX rats decreased bone turnover and increased bone formation parameters resulting in a positive bone balance that prevented bone loss (in both lower and higher doses) and added extra bone to metaphyses of OVX rats (in higher dose). These findings support the strategy of the use of bone stimulation agents in the prevention of estrogen depletion bone loss (postmenopausal osteoporosis).
Summary
The object of this study was to determine whether prostaglandin E., (PGE2) can prevent ovariectomyinduced cancellous bone loss. Thirty-five 3-month-old female Sprague-Dawley rats were divided into two groups. The rats in the first group were ovariectomized (OVX) while the others received sham operation (sham-OVX). The OVX group was further divided into three treatment groups. The daily doses for the three groups were 0, 1 and 6 mg PGE,/kg for 90 days. Bone histomorphometric analyses were performed on double-fluorescent-labeled undecalcified proximal tibial metaphysis (PTM). We confirmed that OVX induces massive cancellous bone loss (-80%) and a higher bone turnover (+ 143%). The new findings from the present study demonstrate that bone loss due to ovarian hormone deficiency can be prevented by a low-dose (1 mg) daily administration of PGE2. Furthermore, a higher-dose (6 mg) daily administration of PGE2 not only prevents bone loss but also adds extra bone to the proximal tibial metaphyses. PGE_, at the l-mg dose level significantly increased trabecular bone area, trabecular width, trabecular node density, density of node to node, ratio of node to free end, and thus significantly decreased trabecular separation from OVX controls. At this dose level, these same parameters did not differ significantly from sham-OVX controls. However, at the 6-mg dose level PGEz, there were significant increases in trabecular bone area, trabecular width, trabecular node density, density of node to node, and ratio of node to free end, while there was significant decrease in trabecular separation from both OVX and sham-operated controls. The changes in indices of trabecular bone microanatomical structure indicated that PGE2 prevented bone loss as well as the disconnection of existing trabeculae. In summary, PGE2 administration to OVX rats decreased bone turnover and increased bone formation parameters resulting in a positive bone balance that prevented bone loss (in both lower and higher doses) and added extra bone to metaphyses of OVX rats (in higher dose). These findings support the strategy of the use of bone stimulation agents in the prevention of estrogen depletion bone loss (postmenopausal osteoporosis).
Introduction
The positive bone balance (anabolic) effects of exogenous prostaglandin E2 (PGE_) on bone are well known: daily administration of PGE: can increase bone mass in both animals [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] and man [13] [14] [15] .
Previously, we reported that exogenous PGE2 not only increased bone mass in intact male and female rats by activating bone modeling and remodeling in favor of bone formation [16] [17] [18] [19] [20] [21] [22] , but also restored bone to osteopenic ovariectomized (OVX) rats [16] [17] [18] . In light of these facts, we postulated that PGE2 will prevent ovariectomy-induced bone loss if given immediately following ovariectomy. The present study tested this postulate. It used a 90-day experimental period to allow both bone loss in OVX rats and bone gain in PGE2-treated rats to reach a new steady state [19, 23] . This period equals at least two to three bone remodeling cycles [ 19, 24] .
Materials and Methods
Thirty-five 3-months-old virgin female Sprague-Dawley rats, weighing approximately 255 g (Charles River Laboratory, Inc., Portage, MI) were acclimated to local vivarium conditions (24cC and 12 h/12 h light-dark cycle) for 7 days. During the experimental period, each animal was housed in a separate plastic module (21 x 32 x 20 cm) and allowed free access to water and a pelleted (commercial) natural-product diet (Rodent Laboratory Chow 5001, Ralston-Purina Co., St. Louis, MO), which contained 1.46% of calcium, 0.99% of phosphorus and 4.96 IU/g of Vit. D3. The rats were divided into five groups (6-9 rats per group). The first group (six rats) was sacrificed at day 0 for baseline or basal controls. Group 2 (six rats) was sham-OVX and treated simultaneously with a vehicle injection for 90 days. Groups 3-5 were OVX and treated simultaneously with 0 (six rats), 1 (eight rats) and 6 (nine rats) mg PGE2/kg/day, respectively, for 90 days. All rats. except those killed at day 0, received daily injections of I ml/kg PGE2 or a vehicle solution. Powdered PGE2 (The Upjohn Co., Kalamazoo, MI) was prepared as previously [19] . Groups 2 (sham-OVX controls) and 3 (OVX controls) received a vehicle (20% ethanol) while group 4 (OVX + 1 ms/ks/day) received 1 mg/ml, and group 5 (OVX + 6 ms/ks/day) received 6 mg/ml daily subcutaneously on the back [19] . All rats received a subcutaneous injection of 25 ms/ks of tetracycline (Achomycin-tetracycline hydrochloride; Lederle Laboratory, Pearl River, NY) on the 14th and 13th day and 10 ms/ks ofcalcein (Sigma Chemical Co., St. Louis, MO) on the 4th and 3rd day before sacrifice.
At autopsy, all rats were anesthetized by intraperitoneally injecting a mixed solution of 50 ms/ks of ketamine hydrochloride (Veterinary Products, Bristol Laboratories, Div. of Bristol-Myers Co., Syracuse, NY) and 10 ms/ks of xylazine (Mobay Corporation, Animal Health Division, Shawnee, KS) at 1 ml/kg body weight. The rats were exsanguinated by heart puncture and the serum was stored frozen, but was not analyzed because there were numerous publications on the subject [11, 16, 19, 25, 26] 2.
1.4
1.2 increases in weight of the liver (42%), lungs (19%), spleen (14%) and adrenal glands (39%) were seen when compared to those of sham controls. Figure 3 shows the changes in left tibial length: 37.7 + 0.92 mm at day 0 (3 months of age) and 39.0 + 0.4 mm at day 90 (6 months of age), a significant increase with age. The tibial length in OVX rats treated with 1 and 6 mg PGEz/kg/day were longer compared to sham-OVX (39.7___0.56 mm at 1 mg and 39.4+0.31 mm at 6 mg vs. 39.0 ___ 0.4 mm at sham-OVX).
Effects in tibial length

Qualitative observation of microradiographs
The primary spongiosa and growth plate were thinner in sham controls than in basal controls (Figs. 4B vs. A) . No obvious bone mass change was found in the secondary spongiosa between basal (3 months of age) and sham (6 months of age) controls.
Thinner and more dense primary spongiosa and less bone mass node to node, and node to free end increased while cortex to free end and free end to free end decreased (Fig. 7) . (Fig. 5) ; (3) decrease in trabecular-bone-based density of node (85%), node to node (89%), node to free end (90%), and an increase in the indices for free end to free end (102%) and cortex to free end (282%) (Fig. 7) . The ratio of node to free end decreased to 13% of those of basal and sham controls ( Table 1) .
Effects of PGEz on 0 VX rats (compared to 0 VX controls).
In PGEz-treated OVX rats, trabecular bone area, width and number increased and trabecular separation decreased. Trabecular bone area increased 343 and 626% over OVX controls for 1-and 6-rag PGEz/kg/day-treated OVX rats. Similarly trabecular width increased 35% for the 6-rag dose, and trabecular number increased 233% and 359% for the 1-and 6-mg doses. Trabecular separation decreased 87% and 91% for l-and 6-mg PGE2/kg/day-treated OVX rats (Fig.  5) . In 1-and 6-mg PGE2/kg/day-treated OVX rats, all tissue-based structural indices increased from 79 to 2187% (Fig. 6) . Trabecular-bone-based density of node, node to node and node to free end were elevated while free end to free end and cortex to free end declined in 1-and 6-rag PGE2/kg/day-treated OVX rats (Fig. 7) . Further, there were 6-and 10-fold increases in node to free end ratios after 1 and 6 mg PGE2 treatment (Table 1) .
Effects of PGE2 on 0 VX rats (compared to sham controls).
In PGE2-treated OVX rats, trabecular bone area in 1-mg PGEz/kg/day-treated OVX rats was unchanged (Fig. 5A ), but trabecular number declined by 21% and trabecular width was elevated by 23% (Figs. 5B and C) . At the 6-rag dose level, percent trabecular bone area increased by 61% and trabecular width by 44% (Fig. 5) . In 1-mg PGE2/kg/day-treated OVX rats, the tissue-based density of cortex to node, free end to free end and node to free end were lower than sham controls (22 to 37%) (Fig. 6) . None of the trabecular bone-based microanatomical structure indices differed from sham controls at both 1-and 6-rag dose levels (Fig. 7) .
Effects on longitudinal bone growth and growth plate thickness
When compared to the rate of longitudinal growth at 3 months of age, the longitudinal growth rate at 6 months of age had decreased by 71%. However OVX controls showed a 21% increase in longitudinal growth rate over sham- Table 1 Ratio of node to free end of proximal tibial trabeculae a OVX controls (Fig. 8A ). In the 6-mg PGE2-treated OVX rats, longitudinal growth rate increased compared to sham (48%) and OVX (22%) controls (Fig.  8A) . Growth plate thickness decreased in sham controls compared to basal controls, while it increased in ovariectomized rats compared to sham controls (33%). During the experimental periods, there was a 5.8 + 0. l-mm new metaphysis generated (mean accumulated longitudinal growth) in sham-OVX control rats, while there was a metaphysis of 6.1_+0.3, 6.3_+0.2 and 6.5+0.2 mm in OVX controls, 1-and 6-mg PGE_-treated OVX rats, respectively (Fig. 8C) : an increase in the latter three groups from the sham controls (Fig. 8C) . •°T 
Effects of PGE2 on OVX rats (compared to OVX controls).
There was a significant decrease in percent osteoid perimeter (27 and 28%), and a significant increase in mineral apposition rate (15 and 29%), bone formation rate-tissue area referent (291 and 652%) and wall width (146 and 170%) in 1-and 6-mg PGE2-treated OVX rats (Figs. 9 and 10A ). Bone formation, resorption, quiescent and remodeling periods were shortened (from 79 to 244%), and the index of activation frequency of bone remodeling decreased (71 and 53%) in PGE2-treated OVX rats (Figs. 10B-F) .
Effects of PGE, on O VX rats (compared to sham-OVX controls).
Except for mineral apposition rate in l-mg PGE2-treated OVX rats, all bone formation parameters were either increased significantly (42 to 270%) or, in the case of the bone resorption parameter, was not changed in the 1-and 6-mg PGE2/kg/daytreated OVX rats (Figs. 9A-F) . Wall width was thicker by 56% in 6-rag PGE2-treated OVX rats (Fig. 10A ). Bone formation, resorption, quiescent and remodeling periods, and activation frequency were nonsignificantly changed in PGE_,-treated OVX rats (Figs. 10B-F) . Furthermore, diffuse-labeled new bone, as an index of woven bone formation, was seen in all 1-and 6-rag PGE_,/kg/day treated rats (0.011+0.006 mm z at 1 mg and 0.022_+0.004 mm 2 at 6 mg, respectively) and was not seen in any basal, sham-OVX or OVX controls.
Discussion
Some interesting cancellous bone data were generated between sham-operated controls (6 months of age) and basal controls (3 months of age). Between 3 and 6 months of age, the trabecular bone area, width and number was nonsignificantly decreased in proximal tibial metaphyses.
But the dynamic parameters show that trabecular labeling perimeter, bone formation rates (bone area and tissue area referent) and longitudinal growth rates declined significantly, while formation and resorption periods were elevated significantly, and trabecular eroded perimeter was not significantly different. Taken all together, these changes indicate that aging decreases bone formation, prolongs bone remodeling, but does not change bone resorption. The age-related changes in the indices of trabecular microanatomical structm'e indicate that the nonsignificant decrease in trabecular bone area between these ages coincides with the thinning of trabeculae and the loss of some disconnected trabeculae (CTF and FTF). At the same time there was no loss of connected trabeculae (NTN). The net effect was that the connections per unit bone area (node/BV and NTN/BV) were improved. Possibly, the explanation is that the mechanical loading on disconnected trabeculae is less than that in connected trabeculae, so that the disconnected trabeculae will be the first to go in age-related bone loss.
The ovariectomy-induced bone loss rat model is widely accepted for studying the prevention and treatment of postmenopausal osteoporosis [39] [40] . In younger rats, ovariectomy results in a dramatic decrease in cancellous bone mass associated with an increase in boneturnoverwith boneresorptionexceeding formation [38] [39] [40] [41] [42] [43] [44] [45] [46] .Our findingsof a decrease in trabecularbonearea,the increment of percent erodedperimeter, percent osteoidandlabelingperimeter, boneformationrate-bone areareferent, andthedecrement of formation, resorption, remodeling andquiescent periodsin OVX controlratsareconsistent with findingsreportedpreviously [38] [39] [40] [41] [42] [43] [44] [45] [46] .Mineral appositionrate wasincreased significantlyin OVX ratsin otherreports [23, 44, 47] , but this changewasnot seenin the currentstudy.Wronskiet al. reportedthat longitudinal growthin proximaltibial metaphyses increased significantly in OVX rats 14and35days postovariectomy andreturned to controllevelsthereafter [23,38,42.44] . However, westillobserved asignificantly increased longitudinal growthrateat90days postovariectomy. Theactivation frequency indexwaselevated in ourOVX rats which further confirmsthe increment in bone turnover.Eventhoughbone formationperunit boneareaincreased in OVX rats,boneformationrate-tissue areareferent declined in OVX rats,indicatingthe absolutebone-forming area decreased in theserats.
Wealsodetailedthe changes in microanatomical structural indicesof trabecutarbonein proximal tibial metaphyses in OVX ratsin thecurrent paper, data lackingin previous reports [38] [39] [40] [41] [42] [43] [44] [45] [46] . Theseindicesshowed thattheOVX-induced bonelossis accompanied by decreased interconnectedness of normaltrabecular structuralpattern.The decreased interconnectedness of trabeculae wasmost obviouswhenonecompares the ratio of nodeto freeendbetween OVX and basal andsham-OVX controlrats(Table1).
Thefindingsfromthepresent studydemonstrate thatbonelossdueto ovarian hormone deficiency canbeprevented bya low-dose (1mg)dailyadministration of PGE2. Furthermore a higher-dose (6 mg)daily administration of PGE2 not only prevents bonelossbut alsoaddsextraboneto theproximaltibial metaphyses. PGE2at the l-mgdoselevel significantly increased trabecular bonearea. trabecularwidth,trabecular nodedensity, density of nodetonode, ratioofnodetofree end,andthussignificantly decreased trabecular separation fromOVX controls. At thisdoselevel,these sameparameters did not differsignificantly fromshamoperated controls. However, atthe6-mgdoselevelPGE2, thereweresignificant increases in trabecular bonearea,trabecularwidth, trabecularnodedensity, densityof nodeto node,ratioof nodeto freeend,whiletherewasa significant decrease in trabecular separation fromboth OVX andsham-operated controls. Thechanges in indicesof trabecular bonemicroanatomical structure indicated thatPGE2prevented bonelossaswellasthedisconnection of existing trabeculae (Table1).
Prevention of bonelossafterovariectomy by manyagents, suchasestrogen, parathyroid hormone, bisphosphonate havebeen studied [39, 40, [47] [48] [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] . Estrogen prevents bonelossinduced byovariectomy by inhibitingboneturnover andbone resorption [39, 40, [47] [48] [49] [50] . Bonelossafter ovariectomy can be prevented and restoredby humanparathyroidhormoneby retardingbone resorptionand enhancing boneformation [52] [53] [54] [55] [56] [57] 
